# Moderna, Inc. (MRNA) FY2024 Annual Balance Sheet

- Company: Moderna, Inc. (MRNA)
- Period: As of 2024-12-31
- Filing: FY2024 10-K, filed 2025-02-21, accession number 0001682852-25-000022
- Page: https://plicit.ai/financials/mrna/fy2024-annual-balance-sheet
- Chart image: https://plicit.ai/charts/mrna-fy2024-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 14,142,000,000 US dollars
- **Current assets**: 8,099,000,000 US dollars
- **Non-current assets**: 6,043,000,000 US dollars
- **Liabilities**: 3,241,000,000 US dollars
- **Current liabilities**: 2,206,000,000 US dollars
- **Non-current liabilities**: 1,035,000,000 US dollars
- **Equity**: 10,901,000,000 US dollars
- **Investments**: 5,098,000,000 US dollars
- **Cash and cash equivalents**: 1,927,000,000 US dollars
- **Prepaid expenses and other current assets**: 599,000,000 US dollars
- **Accounts receivable, net**: 358,000,000 US dollars
- **Inventory**: 117,000,000 US dollars
- **Investments, non-current**: 2,494,000,000 US dollars
- **Property, plant and equipment, net**: 2,196,000,000 US dollars
- **Right-of-use assets, operating leases**: 759,000,000 US dollars
- **Other non-current assets**: 594,000,000 US dollars
- **Accrued liabilities**: 1,427,000,000 US dollars
- **Accounts payable**: 405,000,000 US dollars
- **Other current liabilities**: 221,000,000 US dollars
- **Deferred revenue**: 153,000,000 US dollars
- **Operating lease liabilities, non-current**: 671,000,000 US dollars
- **Other non-current liabilities**: 267,000,000 US dollars
- **Deferred revenue, non-current**: 58,000,000 US dollars
- **Financing lease liabilities, non-current**: 39,000,000 US dollars
- **Retained earnings**: 10,045,000,000 US dollars
- **Additional paid-in capital**: 866,000,000 US dollars
- **Preferred stock, $0.0001; 162 shares authorized as of December 31, 2024 and 2023; no shares issued or outstanding at December 31, 2024 and 2023**: 0 US dollars
- **Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2024 and 2023; 386 and 382 shares issued and outstanding as of December 31, 2024 and 2023, respectively**: 0 US dollars
- **Accumulated other comprehensive loss**: negative 10,000,000 US dollars
- **Gross equity (calculated)**: 10,911,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.